<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>329</serviceExecutionTime><Drug id="8453"><DrugName>rFGF-2, Chiron</DrugName><DrugSynonyms><Name><Value>rbFGF, Chiron</Value></Name><Name><Value>rFGF-2, Chiron</Value></Name><Name><Value>recombinant fibroblast growth factor, Chiron</Value></Name><Name><Value>recombinant basic fibroblast growth factor, Chiron</Value></Name><Name><Value>Basic fibroblast growth factor</Value></Name></DrugSynonyms><CompanyOriginator id="19831">Scios Inc</CompanyOriginator><CompaniesSecondary><Company id="15358">Cephalon Inc</Company><Company id="15385">Chiron Corp</Company><Company id="17373">Ethicon Inc</Company><Company id="19831">Scios Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="8453" type="Drug"><TargetEntity id="135325" type="siDrug">Basic fibroblast growth factor</TargetEntity></SourceEntity><SourceEntity id="15358" type="Company"><TargetEntity id="4295905909" type="organizationId">Cephalon Inc</TargetEntity></SourceEntity><SourceEntity id="15385" type="Company"><TargetEntity id="5036161975" type="organizationId">Chiron Corp</TargetEntity></SourceEntity><SourceEntity id="17373" type="Company"><TargetEntity id="4298362385" type="organizationId">Johnson &amp; Johnson Medical Ltd</TargetEntity></SourceEntity><SourceEntity id="19831" type="Company"><TargetEntity id="4295907891" type="organizationId">Scios LLC</TargetEntity></SourceEntity><SourceEntity id="1001" type="ciIndication"><TargetEntity id="D020196" type="MeSH"></TargetEntity><TargetEntity id="-1612737435" type="omicsDisease"></TargetEntity><TargetEntity id="1441" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="23" type="ciIndication"><TargetEntity id="I20" type="ICD10"></TargetEntity><TargetEntity id="10002383" type="MEDDRA"></TargetEntity><TargetEntity id="D000787" type="MeSH"></TargetEntity><TargetEntity id="-1965112918" type="omicsDisease"></TargetEntity><TargetEntity id="223" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="260" type="ciIndication"><TargetEntity id="10034636" type="MEDDRA"></TargetEntity><TargetEntity id="D016491" type="MeSH"></TargetEntity><TargetEntity id="-817414410" type="omicsDisease"></TargetEntity><TargetEntity id="260" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="347" type="ciIndication"><TargetEntity id="D014945" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="637" type="ciIndication"><TargetEntity id="10061255" type="MEDDRA"></TargetEntity><TargetEntity id="D007511" type="MeSH"></TargetEntity><TargetEntity id="-352987161" type="omicsDisease"></TargetEntity><TargetEntity id="1754" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="80" type="ciIndication"><TargetEntity id="10011078" type="MEDDRA"></TargetEntity><TargetEntity id="D003327" type="MeSH"></TargetEntity><TargetEntity id="-1572475765" type="omicsDisease"></TargetEntity><TargetEntity id="221" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="62" type="Action"><TargetEntity id="1519" type="Mechanism">Angiogenesis Inducers</TargetEntity></SourceEntity><SourceEntity id="PTGT-00741" type="ciTarget"><TargetEntity id="29700784322473" type="siTarget">Fibroblast growth factor 2</TargetEntity><TargetEntity id="259" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="1001">Nervous system injury</Indication><Indication id="23">Angina</Indication><Indication id="260">Peripheral vascular disease</Indication><Indication id="347">Wound healing</Indication><Indication id="637">Ischemia</Indication><Indication id="80">Coronary artery disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="3617">FGF-2 ligand</Action></ActionsPrimary><ActionsSecondary><Action id="62">Angiogenesis stimulator</Action></ActionsSecondary><Technologies><Technology id="85">Protein recombinant</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2017-08-18T06:48:09.000Z</LastModificationDate><ChangeDateLast>2016-10-27T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Chiron was developing recombinant human basic fibroblast growth factor (rFGF-2) expressed in yeast for the potential treatment of coronary artery disease (CAD) and peripheral artery disease (PAD), for which it was in phase II trials in 1999 [&lt;ulink linkID="304346" linkType="reference"&gt;304346&lt;/ulink&gt;], [&lt;ulink linkID="359192" linkType="reference"&gt;359192&lt;/ulink&gt;], [&lt;ulink linkID="402675" linkType="reference"&gt;402675&lt;/ulink&gt;]. By March 2003, Chiron had discontinued development of rFGF-2 and was considering out-licensing options [&lt;ulink linkID="481460" linkType="reference"&gt;481460&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The product has also been considered to have potential applications in wound healing, tissue grafting, nerve regeneration and treatment of ischemia [&lt;ulink linkID="226115" linkType="reference"&gt;226115&lt;/ulink&gt;]. It was being jointly developed with Cephalon and &lt;ulink linkID="17432" linkType="Company"&gt;Ethicon&lt;/ulink&gt; (&lt;ulink linkID="17332" linkType="Company"&gt;Johnson &amp;amp; Johnson&lt;/ulink&gt;) [&lt;ulink linkID="160695" linkType="reference"&gt;160695&lt;/ulink&gt;], [&lt;ulink linkID="179120" linkType="reference"&gt;179120&lt;/ulink&gt;]. However, no development has been reported by Cephalon or &lt;ulink linkID="17432" linkType="Company"&gt;Ethicon&lt;/ulink&gt; since 1994.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;CORONARY ARTERY DISEASE&lt;/subtitle&gt;By July 2001, the company was reviewing the development of this product as part of a prioritization of its pipeline, but had  not made any firm decision [&lt;ulink linkID="417045" linkType="reference"&gt;417045&lt;/ulink&gt;]. In April 2002, rFGF-2 still appeared in Chiron's pipeline as being in phase II development [&lt;ulink linkID="456332" linkType="reference"&gt;456332&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2001, Chiron presented the 180 day results of its phase II FIRST trial (rFGF-2 initiating revascularization support trial) of rFGF-2 in patients (n = 337) with severe CAD; preliminary results were released in March 2000. The primary endpoint of increased exercise tolerance did not reach statistical significance, but improvement in several clinically relevant secondary endpoints, including reduction in angina frequency was observed compared with placebo [&lt;ulink linkID="359192" linkType="reference"&gt;359192&lt;/ulink&gt;], [&lt;ulink linkID="360751" linkType="reference"&gt;360751&lt;/ulink&gt;], [&lt;ulink linkID="361053" linkType="reference"&gt;361053&lt;/ulink&gt;], [&lt;ulink linkID="397058" linkType="reference"&gt;397058&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Phase II trials of rFGF-2 began in November 1998, following the encouraging results from the phase I trial of rFGF-2 in patients with severe CAD [&lt;ulink linkID="304346" linkType="reference"&gt;304346&lt;/ulink&gt;], [&lt;ulink linkID="316746" linkType="reference"&gt;316746&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;PERIPHERAL ARTERY DISEASE&lt;/subtitle&gt;In January 2001, Chiron presented results of a three-arm phase II trial of rFGF-2 in patients (n = 190) with moderate-to severe claudication associated with PAD. The primary efficacy endpoint of peak walking time showed positive trends [&lt;ulink linkID="397058" linkType="reference"&gt;397058&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;ANGINA&lt;/subtitle&gt;In February 1999, enrollment into a trial of rFGF in patients with severe angina began. Up to 30 patients were expected to be enrolled on the trial which was sponsored by Chiron and carried out by researchers at UCSF and Stanford Health Care [&lt;ulink linkID="321296" linkType="reference"&gt;321296&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In November 1999, Chiron licensed rights to rFGF2 from Scios. Scios has launched its rFGF2 as &lt;ulink linkID="3128" linkType="Drug"&gt;trafermin&lt;/ulink&gt; (qv) [&lt;ulink linkID="346050" linkType="reference"&gt;346050&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt; &lt;br&gt;&lt;/br&gt;The method of producing the protein is claimed in the associated patent, WO-09005184. Chiron holds an older patent, EP-00340986, which claims the expression of a heterologous form of fibroblast growth factor.&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;&lt;subtitle&gt;Robert Ertner &amp;amp; Alan David Kaye&lt;/subtitle&gt;Department of Anesthesiology and Pharmacology, Texas Tech Medical Center, Lubbock, TX&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Submission date: 27 January 2003&lt;/subtitle&gt;&lt;subtitle&gt;Publication date: 05 March 2003&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;The growth factor FGF-2 is a cell-surface heparin sulfate proteoglycan expressed in many tissues of the body [&lt;ulink linkType="reference" linkID="96000"&gt;96000&lt;/ulink&gt;]. Also known as basic FGF (as distinct from acidic or FGF-1), it is an 18-kDa glycosylated polypeptide consisting of 154 amino acid residues [&lt;ulink linkType="reference" linkID="479391"&gt;479391&lt;/ulink&gt;]. It is known to induce growth and mitosis of fibroblasts and neural cells, and has angiogenic properties.&lt;/para&gt;&lt;para&gt;Using recombinant DNA technology, Chiron is currently developing recombinant basic human fibroblast growth factor (rFGF-2) as a potential treatment for several disease states. The drug has shown promise in the treatment of wound healing, tissue grafting, nerve regeneration and ischemic vascular disease [&lt;ulink linkType="reference" linkID="226115"&gt;226115&lt;/ulink&gt;]. It is for the treatment of ischemic coronary artery disease (CAD) and peripheral vascular disease (PVD) that the drug is currently undergoing phase II trials [&lt;ulink linkType="reference" linkID="304346"&gt;304346&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="359192"&gt;359192&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="402675"&gt;402675&lt;/ulink&gt;]. Chiron has entered into a development partnership with Cephalon and &lt;ulink linkType="Company" linkID="17432"&gt;Ethicon&lt;/ulink&gt; for the purposes of bringing rFGF-2 to the market.&lt;/para&gt;&lt;para&gt;Current treatments for PVD and CAD consist of medical modification of disease progression by dietary alteration, lipid lowering drugs and exercise. Interventions include percutaneous angioplasty, stent placement, or vascular bypass. Some patients, due to the complexity or the extent of the lesion, are not candidates for these interventions. It is these patients who would benefit most from a medicine that could initiate homologous auto-revascularization and collaterization.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;The gene sequences for human basic and acidic FGF are both known. The gene sequence responsible for the expression of FGF was synthesized, cloned into the appropriate expression vector and introduced into E Coli. The bacteria then produced relatively large quantities of this substance [&lt;ulink linkType="reference" linkID="473462"&gt;473462&lt;/ulink&gt;]. By using the yeast Saccharomyces cerevisiae instead of E Coli, it was possible to express and subsequently isolate large quantities of rFGF-2 [&lt;ulink linkType="reference" linkID="226115"&gt;226115&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;The main outcome of preclinical investigations with rFGF-2 has been establishing the mode of action of the molecule in various circumstances and, thus, its possible therapeutic potential. Various models have been utilized including ischemia-reperfusion injury, coronary angioplasty, excisional injury and cancer.&lt;/para&gt;&lt;para&gt;Coronary-perfused mouse hearts were pretreated with rFGF-2 1 microg/kg before the onset of ischemia in order to determine the effect of the molecule on ischemia-reperfusion injury. The fall in left ventricular pressure (LVP) during early ischemia was attenuated in hearts pretreated with rFGF-2. The drug also improved the rate of recovery of LVP compared with control and preserved maximum rates of contraction and relaxation. Cai2+ (internal Ca2+) was similar in both groups at baseline, and inhibition of NO synthase (NOS2) obliterated the protective effects of rFGF-2. Administration of rFGF-2, therefore, attenuated myocardial stunning independent of alterations in Cai2+ by stimulating NO production via a NOS2-dependant pathway [&lt;ulink linkType="reference" linkID="473498"&gt;473498&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In order to investigate the possible effect of rFGF-2 on restenosis after coronary angioplasty or stent placement, a single intracoronary dose of rFGF-2 was administered in a pig model of coronary atherosclerosis. A dose of rFGF-2 2 microg/kg did not affect neointima formation or produce angiographic or echographic late lumen loss, intimal hyperplasia or atrial remodeling different from control. These results suggest that rFGF-2 does not aggravate restenosis, thus permitting further investigation of rFGF-2 in therapeutic angiogenesis [&lt;ulink linkType="reference" linkID="473465"&gt;473465&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The influence of rFGF-2 in age-related wound repair was examined in a standardized excisional injury model in mice. Angiogenesis, re-epithelialization and collagen synthesis were delayed in aged mice and wounds contained substantially less FGF-2. Subcutaneous addition of rFGF-2 to either young or aged mice produced a far greater angiogenic effect in young than aged mice. It seems that, although the presence of FGF-2 is important in wound healing, a decline in responsiveness to the epithelial factor may also contribute to the age-related delay in wound angiogenesis and this should be borne in mind in clinical investigation of the therapy [&lt;ulink linkType="reference" linkID="473457"&gt;473457&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;FGF-2 has also been implicated in tumor angiogenesis and this was investigated in non-small-cell lung cancer (NSCLC) cell lines, surgical specimens and control cell lines. Initial results demonstrated an elevated level of FGF-2 in almost all NSCLC cell lines; FGF-2 was not secreted by these cells into the extracellular space. In low FGF-2-producing NSCLC and control cell lines, FGF-2 receptors (FGFR-2) were located at the plasma membrane and these cells were unresponsive to rFGF-2. In the majority of NSCLC cell lines, however, FGFR-2 were located intracellularly and, in this case, the cells were insensitive to both the proliferative effect of rFGF-2 and growth inhibition by FGF-2 neutralizing antibodies. This should minimize the dangers of rFGF-2 cardiovascular therapy in cancer patients [&lt;ulink linkType="reference" linkID="473458"&gt;473458&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;A phase I trial of rFGF-2 administered as an intracoronary or intravenous single-dose infusion revealed bimodal clearance of the drug. The study examined doses ranging from 0.33 to 48 microg/kg. Over this range, rFGF-2 displayed a bimodal elimination pattern with a distribution half-life of 21 min and a terminal elimination half-life of 7.6 h. Due to the tendency of rFGF-2 to form complexes with heparin, elimination was prolonged in the presence of systemically administered heparin. Despite these results, no clear pharmacodynamic or pharmacokinetic dose-response relationship has been clearly established [&lt;ulink linkType="reference" linkID="473450"&gt;473450&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;The safety of rFGF-2 was assessed in healthy rats and pigs administered 30 to 300 and 0.65 to 20 microg/kg rFGF-2, respectively. The only toxicities noted were a slight increase in selected organ weights in rats and a slight reversible tachycardia in unconscious pigs. Transient hypotension was also observed, although this is a known pharmacological effect of the molecule [&lt;ulink linkType="reference" linkID="473484"&gt;473484&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;&lt;subtitle&gt;CAD and Angina:&lt;/subtitle&gt;Chiron has studied rFGF-2 in a phase I open-label, two-center trial. The study included 66 patients (52 administered intracoronary rFGF-2 and 14 administered the drug intravenously) subjected to increasing doses of rFGF-2. The drug was well tolerated at doses up to 36 microg/kg [&lt;ulink linkType="reference" linkID="318382"&gt;318382&lt;/ulink&gt;]. There were statistically significant increases in patients' exercise tolerance and in their subjective scoring of their quality of life. Furthermore, the frequency of angina and regional LV function as assessed by MRI also improved [&lt;ulink linkType="reference" linkID="316746"&gt;316746&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;&lt;subtitle&gt;CAD:&lt;/subtitle&gt;In November 1998, rFGF-2 entered phase II trials for the treatment of CAD. In March 2000, the preliminary results from the so-called 'FIRST' (FGF-2 Initiation Revascularization Support Trial) trial were published. This study was double blinded, randomized, and placebo controlled. While the study's primary target of improvement of exercise time after 3 months of treatment was not reached, angina frequency was significantly reduced. Three doses of rFGF-2 (0.3, 3.0, and 30 microg/kg) were administered to 337 patients in the study as single intracoronary infusion and patients were evaluated at 90 and 180 days. Functional MRI of the heart revealed no significant difference between the two groups [&lt;ulink linkType="reference" linkID="359192"&gt;359192&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="360751"&gt;360751&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="361053"&gt;361053&lt;/ulink&gt;]. The official results confirmed the preliminary results, but also showed that the attenuation of angina frequency at 90 days persisted up to 180 days [&lt;ulink linkType="reference" linkID="397058"&gt;397058&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;PVD:&lt;/subtitle&gt;In January 2001, Chiron reported results from a phase II trial investigating rFGF-2 as a treatment for intermittent claudication. The study, 'TRAFFIC' (Therapeutic Angiogenesis with FGF-2 for Intermittent Claudication), was a multi-center, randomized, double-blinded, placebo-controlled study in 190 patients with moderate to severe claudication. The study compared a single intra-arterial infusion of rFGF-2 30 microg/kg administered to both legs on day 1 with two doses on days 1 and 30. The study's primary endpoint, a significant elevation in the peak walking time (PWT) at 90 days post-infusion, did not reach statistical significance despite an increasing trend. A secondary analysis, however, showed a statistically significant difference in PWT between the single-dose and placebo groups at 90 days [&lt;ulink linkType="reference" linkID="397058"&gt;397058&lt;/ulink&gt;]. Further analysis of the data collected from the TRAFFIC study as it pertains to specific patient subgroups continues to be released [&lt;ulink linkType="reference" linkID="473470"&gt;473470&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="473477"&gt;473477&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Wound Healing:&lt;/subtitle&gt;Perhaps the most obvious application of rFGF-2 is its potential use as a wound-healing agent for surgical incisions, burns, and ischemic wounds.&lt;/para&gt;&lt;para&gt;Data from a Chinese study examining the use of bovine rFGF on burn patients and patients with non-healing cutaneous wounds were released in 2000. The patients were divided into three groups consisting of burn wounds, donor sites, or chronic cutaneous ulcers. Each group was randomized and received either bovine rFGF or placebo. A total of 1024 patients were enrolled in the study. The 624 patients placed in the burn group were divided into 324 patients receiving the drug and 330 controls. The 826 patients placed into the donor site group were divided into 509 patients receiving the drug and 317 controls. The 185 patients enrolled in the chronic dermal ulcer group functioned as their own controls. Using photography, clinical evaluation and histological examination, it was found that all three groups experienced improvement in wound healing. The rFGF-treated superficial second-degree burns healed in 9.89 days on average compared with 12.35 days for placebo. The rFGF-treated deep second-degree burns healed in 17.04 days compared with 21.21 days for placebo. The rFGF-treated donor sites healed in 10.68 days compared with 14.74 days for the placebo group. All of the chronic dermal ulcers healed within 6 weeks with the exception of 12 rFGF-treated wounds [&lt;ulink linkType="reference" linkID="473455"&gt;473455&lt;/ulink&gt;]. A similar study showed almost the same results for the treatment of superficial and deep second-degree burn wounds in 600 patients treated topically with 150 AU/cm2 of rFGF-2 [&lt;ulink linkType="reference" linkID="473460"&gt;473460&lt;/ulink&gt;]. Statistical analyses of both of the above studies showed that the improvement in wound healing times were statistically significant.&lt;/para&gt;&lt;para&gt;Another study, also carried out in China, showed comparable results for the treatment of non-healing skin ulcers resulting from trauma, diabetes, pressure-related ischemia (decubiti) and radiation. Twenty-eight patients with 33 wounds refractory to conventional therapy were treated with 150 AU/cm2 rFGF-2 for four weeks. Eighteen of the patients wounds healed after only 2 weeks of treatment. An additional four healed after 3 weeks, and another eight healed after 4 weeks. Only three wounds failed to heal after 4 weeks but resolved after 30, 40, and 42 days [&lt;ulink linkType="reference" linkID="473448"&gt;473448&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Despite these rather promising results, rFGF-2 has not begun phase I trials for the treatment of wounds in the US. It is unknown at present whether or not Chiron is planning to pursue this indication in the US.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side Effects and Contraindications&lt;/subtitle&gt;Few studies to date indicate any significant side effects of rFGF-2, although increasing doses of intravenous rFGF-2 have been associated with hypotension and tachycardia [&lt;ulink linkType="reference" linkID="473450"&gt;473450&lt;/ulink&gt;]. The phase I trials in CAD supported this; while doses up to 36 micro were well tolerated, two of ten patients who received rFGF-2 48 microg/kg developed significant hypotension [&lt;ulink linkType="reference" linkID="318382"&gt;318382&lt;/ulink&gt;]. The only contraindication to the use of rFGF-2 would be the presence of a tumor whose malignancy would be potentiated by the presence of increased levels of this molecule such as pancreatic carcinoma, hepatocellular carcinoma  [&lt;ulink linkType="reference" linkID="473454"&gt;473454&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="479395"&gt;479395&lt;/ulink&gt;], and NSCLC [&lt;ulink linkType="reference" linkID="473458"&gt;473458&lt;/ulink&gt;], although preclinical trials suggested that this effect might be minimal [&lt;ulink linkType="reference" linkID="473458"&gt;473458&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;Given the disappointing results of the phase II trials of rFGF-2 for use in CAD and PVD, it is unlikely that this drug will find a significant market due to its cost-to-benefit ratio, even if it does prove to reduce anginal frequency. If Chiron and Scios (the company from which Chiron licensed the rights to rFGF-2) explore the drug as a therapeutic option for burns and chronic wounds, however, the potential for profit would be substantial. Current development of rFGF-2 is in conjunction with Cephalon and &lt;ulink linkType="Company" linkID="17432"&gt;Ethicon&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="160695"&gt;160695&lt;/ulink&gt;], although it is unclear whether this partnership will continue given the results of the FIRST and TRAFFIC studies. Chiron itself is a growing company and in 2001 reported over $1 billion in revenues. This may signal that it may be able to continue to develop rFGF-2 even if its development partners decline to continue with further investigations [&lt;ulink linkType="reference" linkID="437995"&gt;437995&lt;/ulink&gt;].&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="80">Coronary artery disease</Indication><StatusDate>2003-03-11T00:00:00.000Z</StatusDate><Source id="481460" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1001">Nervous system injury</Indication><StatusDate>2003-03-11T00:00:00.000Z</StatusDate><Source id="481460" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="637">Ischemia</Indication><StatusDate>2003-03-11T00:00:00.000Z</StatusDate><Source id="481460" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="347">Wound healing</Indication><StatusDate>2003-03-11T00:00:00.000Z</StatusDate><Source id="481460" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="260">Peripheral vascular disease</Indication><StatusDate>2003-03-11T00:00:00.000Z</StatusDate><Source id="481460" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="23">Angina</Indication><StatusDate>2003-03-06T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17373">Ethicon Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1001">Nervous system injury</Indication><StatusDate>2003-03-11T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17373">Ethicon Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="347">Wound healing</Indication><StatusDate>2003-03-11T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15358">Cephalon Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1001">Nervous system injury</Indication><StatusDate>2003-03-11T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15358">Cephalon Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="347">Wound healing</Indication><StatusDate>2003-03-11T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19831">Scios Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="80">Coronary artery disease</Indication><StatusDate>1999-11-02T00:00:00.000Z</StatusDate><Source id="346050" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19831">Scios Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="347">Wound healing</Indication><StatusDate>1999-11-02T00:00:00.000Z</StatusDate><Source id="346050" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19831">Scios Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="637">Ischemia</Indication><StatusDate>1999-11-02T00:00:00.000Z</StatusDate><Source id="346050" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19831">Scios Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1001">Nervous system injury</Indication><StatusDate>1999-11-02T00:00:00.000Z</StatusDate><Source id="346050" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17373">Ethicon Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1001">Nervous system injury</Indication><Source id="160695" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17373">Ethicon Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="347">Wound healing</Indication><Source id="160695" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1001">Nervous system injury</Indication><Source id="226115" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="260">Peripheral vascular disease</Indication><StatusDate>2000-04-01T00:00:00.000Z</StatusDate><Source id="359192" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="637">Ischemia</Indication><Source id="226115" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="80">Coronary artery disease</Indication><StatusDate>1998-11-12T00:00:00.000Z</StatusDate><Source id="304346" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="80">Coronary artery disease</Indication><Source id="226115" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="23">Angina</Indication><StatusDate>1999-02-01T00:00:00.000Z</StatusDate><Source id="321296" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15385">Chiron Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="347">Wound healing</Indication><Source id="226115" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15358">Cephalon Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1001">Nervous system injury</Indication><Source id="179120" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15358">Cephalon Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="347">Wound healing</Indication><Source id="179120" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00741"><Name>FGF-2 ligand</Name><SwissprotNumbers><Swissprot>P03969</Swissprot><Swissprot>P09038</Swissprot><Swissprot>P12226</Swissprot><Swissprot>P13109</Swissprot><Swissprot>P15655</Swissprot><Swissprot>P20003</Swissprot><Swissprot>P48798</Swissprot><Swissprot>P48799</Swissprot><Swissprot>P48800</Swissprot><Swissprot>Q60487</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="17332">Johnson &amp; Johnson</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="23137">Novartis AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>3</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>1</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><Deals><Deal id="111898" title="Chiron to obtain rights to a recombinant human basic fibroblast growth factor from Scios   "/><Deal id="118193" title="Cephalon to codevelop certain Chiron neurological drugs worldwide excluding Japan "/><Deal id="118196" title="Chiron and Ethicon to codevelop rFGF2  "/></Deals><PatentFamilies><PatentFamily id="1014504" number="WO-00217956" title="Stabilized FGF formulations containing reducing agents"/><PatentFamily id="1273964" number="WO-09005184" title="Expression and processing of authentic FGF's in yeast."/><PatentFamily id="177144" number="WO-00166595" title="Human FGF-23 gene and gene expression products"/><PatentFamily id="52604" number="WO-02058720" title="Angiogenically Effective Unit Dose Of Fgf-2 And Method Of Use"/><PatentFamily id="768900" number="WO-00168125" title="Methods And Compositions For The Treatment And Prevention Of Erectile Dysfunction"/><PatentFamily id="866915" number="WO-00198346" title="Methods and compositions for the treatment of peripheral artery disease"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"/><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>